Uppdaterad analys av Danske Bank efter första kvartalet
Sprint Bioscience - Capital raising in focusSprint Bioscience is progressing gradually. In April 2020, the magazine Science Advances published pre-clinical data on the company's VPS34 inhibitor project, which we argue increases the likelihood of it reaching an out-licensing deal. For PIP4K2, its partner Petra Pharma is scaling up drug substance in order to start the planned Phase 1 study, although it is likely to be delayed due to the COVID-19 outbreak. Click here to access report